Caixin
Dec 18, 2018 07:46 PM
BUSINESS & TECH

Shanghai Biotech Firm Wins Approval For Cutting-Edge Melanoma Drug

Shanghai Junshi Biosciences Co. Ltd. has won approval to launch a PD-1 inhibitor — an injectable cancer-fighting drug — in China. Photo: VCG
Shanghai Junshi Biosciences Co. Ltd. has won approval to launch a PD-1 inhibitor — an injectable cancer-fighting drug — in China. Photo: VCG

Shanghai Junshi Biosciences Co. Ltd. has won approval to launch a novel cancer drug in China, where it will compete with two U.S. rivals.

The injectable medicine belongs to a class of drugs known as PD-1 inhibitors, which work by reversing the cancer’s suppression of a patient’s immune system and help the immune system target cancer cells.

The drug, which is used to treat certain types of melanoma, received a green light from National Medicine Products Administration on Monday, the regulator said (link in Chinese).

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.